Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C

Gastroenterology

Volumn 146, Issue 3, 2014, Pages

  Buti, Maria ^a   Agarwal, Kosh ^b   Horsmans, Yves ^c   Sievert, William ^d   Janczewska, Ewa ^e   Zeuzem, Stefan ^f   Nyberg, Lisa ^g   Brown Jr , Robert S ^h   Hézode, Christophe ⁱ   Rizzetto, Mario ^j   Paraná, Raymundo ^k   De Meyer, Sandra ^l   De Masi, Ralph ^m   Luo, Donghan ^m   Bertelsen, Kirk ^m   Witek, James ^m  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d MONASH MEDICAL CENTRE   (Australia)

^e ID Clinic   (Poland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g KAISER PERMANENTE   (United States)

^h Columbia University College of Physicians and Surgeons ^*  (United States)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j UNIVERSITY OF TURIN   (Italy)

^k FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^l JANSSEN RESEARCH FOUNDATION   (Belgium)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Clinical Trial; DAA; OPTIMIZE; Protease Inhibitor

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; AGED; ANEMIA; ANORECTAL DISEASE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERURICEMIA; INFECTION; INJECTION SITE REACTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

CLINICAL TRIAL; DAA; OPTIMIZE; PROTEASE INHIBITOR;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; NAUSEA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84894312806     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.11.047     Document Type: Article

References (15)

1. ® (telaprevir) tablets. Summary of product characteristics. May 2013. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf. Accessed June 4, 2013.
2. ® (telaprevir) tablets. FDA prescribing information. April 2013. http://pi.vrtx.com/files/uspi-telaprevir.pdf. Accessed June 3, 2013.
3. P. Marcellin, X. Forns, and T. Goeser et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 140 2011 459 468
4. D. Ge, J. Fellay, and A.J. Thompson et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
5. Y. Tanaka, N. Nishida, and M. Sugiyama et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
6. N. Akuta, F. Suzuki, and M. Hirakawa et al. Amino acid substitutions in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin Hepatology 52 2010 421 429
7. P. Marcellin, T. Asselah, and N. Boyer Fibrosis and disease progression in hepatitis Hepatology 36 2002 S47 S56
8. Copegus (Ribavirin) Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/11755/SPC. Accessed June 17, 2013.
9. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. J.G. McHutchison, G.T. Everson, and S.C. Gordon et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
11. C. Hézode, N. Forestier, and G. Dusheiko et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
12. Telaprevir FDA Advisory Committee briefing document. April 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf. Accessed September 24, 2013.
13. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
14. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
15. Sievert W, Buti M, Agarwal K, et al. Adherence with telaprevir bid versus every 8 hour dosing in treatment-naïve HCV-infected Patients: results from the phase III OPTIMIZE study. Presented at: 48th Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; April 24-28, 2013. Poster 905.